Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$2,898 Mln
P/E Ratio
--
P/B Ratio
3.84
Industry P/E
--
Debt to Equity
0.01
ROE
-0.28 %
ROCE
-27.52 %
Div. Yield
0 %
Book Value
9.63
EPS
-2.99
CFO
$-466.87 Mln
EBITDA
$-577.53 Mln
Net Profit
$-548.01 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Xenon Pharmaceuticals (XENE)
| -2.12 | 12.00 | -4.08 | -5.26 | 8.67 | 23.57 | 10.82 |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Xenon Pharmaceuticals (XENE)
| 16.81 | 26.22 | 103.12 | 17.32 | 107.77 | 122.39 | -63.31 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.55 | 771.79 | -- | -14.75 | |
| 8.12 | 1,093.17 | 200 | 1.52 | |
| 4.28 | 198.85 | -- | -53.27 | |
| 2.87 | 90.24 | -- | -19.21 |
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include... Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Address: 200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8 Read more
President, CEO & Director
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
President, CEO & Director
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Headquarters
Burnaby, BC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Xenon Pharmaceuticals Inc (XENE) stood at $ 798 Mln as on 31-Dec-24
The share price of Xenon Pharmaceuticals Inc (XENE) is $38.37 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Xenon Pharmaceuticals Inc (XENE) has given a return of 8.67% in the last 3 years.
Xenon Pharmaceuticals Inc (XENE) has a market capitalisation of $ 2,898 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Xenon Pharmaceuticals Inc (XENE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Xenon Pharmaceuticals Inc (XENE) and enter the required number of quantities and click on buy to purchase the shares of Xenon Pharmaceuticals Inc (XENE).
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Address: 200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8
The CEO & director of Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.. is Xenon Pharmaceuticals Inc (XENE), and CFO & Sr. VP is Mr. Ian C. Mortimer C.M.A., CPA, M.B.A..
There is no promoter pledging in Xenon Pharmaceuticals Inc (XENE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
145
|
|
|
86
|
|
|
23
|
|
|
22
|
| Xenon Pharmaceuticals Inc. (XENE) | Ratios |
|---|---|
|
Return on equity(%)
|
-27.85
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Xenon Pharmaceuticals Inc (XENE) was $0 Mln.
$0.53
(
